Latest Opl News

Opyl Limited has formalized its partnership with UK-based Innovatrix Capital, positioning its AI platform TrialKey at the forefront of clinical trial failure insurance. This deal not only validates Opyl’s technology but also opens doors to global biotech markets and valuable data streams.

Opyl Limited has secured three key partnerships validating its AI-driven TrialKey platform, completed a strategic review to boost AI capabilities, and strengthened its balance sheet with a $1.5 million capital raise and Bitcoin investment.

Opyl Limited has taken a bold step into digital assets by acquiring approximately 2 Bitcoin and securing a $2 million finance facility backed by these holdings, signaling a strategic pivot towards blockchain integration in healthcare technology.

Opyl Limited’s AI platform TrialKey has partnered with UK insurer Innovatrix to launch a pioneering parametric insurance product that protects biotech firms from the financial risks of clinical trial failures.

Opyl Limited has secured strategic collaborations with two leading contract research organisations, integrating its AI-driven TrialKey platform into cardiovascular, oncology, and rare disease clinical trials to enhance trial design and accelerate commercial growth.

Opyl Limited unveils a bold strategic pivot to enhance its AI-driven drug discovery platform, leveraging a vast proprietary dataset and leadership upgrades to redefine clinical trial innovation.

Opyl Limited has successfully raised $1.5 million through an oversubscribed placement to accelerate the growth of its AI-driven clinical trial platform, Trialkey. The capital injection underscores strong investor confidence as the company prepares for a pivotal expansion phase.

Opyl Limited reports strong progress in AI-driven clinical trial optimisation with active commercial initiatives, strategic partnerships, and a planned capital raise to support growth amid tight cash reserves.

Opyl Limited has entered a strategic partnership with Avion, integrating its AI-powered TrialKey platform to enhance clinical trial design and execution across the APAC region.

Opyl Limited's Q2 FY25 update reveals robust progress through key partnerships, a new AI Biotech Fund launch, and strengthened financial footing, positioning the company for expanded influence in clinical trial optimisation.